Navigation Links
TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects
Date:12/1/2008

rended toward statistical significance on reduction in spontaneous pain. In addition, a statistically significant pain-reducing effect was observed for the 150 mg dose through 4.5 hours post-dosing.

NGX426 was well tolerated and all subjects completed the three treatment periods. There were no serious or medically important adverse events or changes on laboratory or ECG parameters. The most common adverse events associated with NGX426 administration were mild somnolence and dizziness.

"We are very encouraged by these results that show an analgesic effect for NGX426 in this well-accepted pain model," said Ev Graham, Chief Executive Officer of TorreyPines. "As an oral, non-opioid pain agent, NGX426 could address the significant and documented unmet needs in treating a range of chronic pain conditions including neuropathic pain and acute or prophylactic treatment of migraine. These data, as well as data from our on-going Phase I multiple dose trial, will help us structure our Phase II development plan for NGX426."

NGX426, an ester prodrug, is an oral form of tezampanel, TorreyPines most advanced product candidate. Pharmacokinetic analyses from two Phase I studies confirmed that when given to humans, NGX426 is rapidly converted to tezampanel, the active moiety. Six Phase II, double-blind, placebo-controlled trials have demonstrated that tezampanel, administered either subcutaneously or intravenously, was more effective than placebo in relieving pain across migraine, nociceptive and neuropathic pain models, including a capsaicin-induced pain model.

In order to pursue the Phase II clinical development of NGX426 TorreyPines intends to explore both strategic and financing initiatives.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results
2. TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
3. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
4. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
5. TorreyPines Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
6. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
7. Heart Failure Patients With Normal Left Ventricular Ejection Fraction Dont Benefit From Treatment With Angiotensin II Receptor Blocker
8. Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils
9. A new Eph receptor tyrosine kinase overexpressed in gastric cancer was found
10. Researchers create first model for retina receptors
11. Turned-off cannabinoid receptor turns on colorectal tumor growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/28/2014)... that aims to make personalized medicine a reality for ... across British Columbia. , The "Genomics for Precision Drug ... of its kind in North America. The project is ... (BCPhA), with the research component led by a team ... Sciences (UBC). It will position the pharmacist as the ...
(Date:10/27/2014)... price tag for informal caregiving of elderly people by ... $522 billion a year, according to a new RAND ... care at minimum wage would cost $221 billion, while ... $642 billion annually. , The study, published online ... estimates about the value of informal caregiving by making ...
(Date:10/27/2014)... different role than previously thought in the opening and ... out of our cells, researchers at Johns Hopkins report. ... right concentrations of sodium and calcium ions in cells ... processes. The new study reveals that a form of ... channels wide. The finding is likely to bring new ...
(Date:10/27/2014)... The 2014 Sharp­Brains Vir­tual ... world’s top sci­en­tists and inno­va­tors work­ing on ... via neuroscience-based inno­va­tion. , Indi­vid­u­als and insti­tu­tions ... bil­lion in 2014 in web-based, mobile and ... func­tion. Growth is poised to con­tinue, fueled ...
(Date:10/27/2014)... Agency (EMA), an EU agency, has gathered information on ... European ADR database, EudraVigilance. Both authorities and pharmaceutical companies ... the database, which provides new knowledge about unknown and ... drug reaction reports on asthma medications approved for – ... (2007 to 2011). In the light of the total ...
Breaking Medicine News(10 mins):Health News:Genomics helps pharmacists target the right drugs for the right patient 2Health News:Cost of informal caregiving for US elderly is $522 billion annually, study finds 2Health News:200 Experts to Discuss and Shape the Future of Brain Health, Gathered Around a Virtual Table 2Health News:200 Experts to Discuss and Shape the Future of Brain Health, Gathered Around a Virtual Table 3Health News:200 Experts to Discuss and Shape the Future of Brain Health, Gathered Around a Virtual Table 4Health News:Adverse drug reactions in children following use of asthma medications 2
... a pregnancy take a general multivitamin supplement in the ... them and their baby, however a recent survey suggests ... in unborn babies but many women do not consider ... based on a recent survey. The survey conducted by ...
... has donated $50,000 to Gilda's Club Worldwide, //an organization that ... in a statement: "When children have cancer, or when their ... places they can turn to for support." , ,"Gilda's ... helping children in need, and so I am very happy ...
... People suffering from Alzheimer’s disease can have loss of ... to test their visual clarity., ,Alzheimer’s disease affects ... symptoms of the disease are decreasing memory, ability to ... Alzheimer’s disease are often disoriented too much to be ...
... may lack a gene called estrogen receptor beta and not ... research funded by National Institute of Environmental Health Sciences reported ... role in moving the egg outside the ovary to be ... is found otherwise throughout in the female reproductive tissues, women ...
... people were infected with HIV by 2004.// This puts the prevalence ... South Africa 's total population is 46.9 million. , ... far higher than the estimate of 4.5 million given by the ... ,The health department said that between 6.29 million ...
... microRNAs may be responsible for birth defects, cancer and ... Institute have used genetically modified mice to see how ... animals. When the mice were grown without the microRNA ... limbs., ,MicroRNA (miRNA) are small RNA molecules that ...
Cached Medicine News:Health News:Britney Spears Donates $50 000 To Support Cancer Patients 2Health News:Britney Spears Donates $50 000 To Support Cancer Patients 3Health News:Over Six Million HIV Infected People In South Africa- Finds A Survey 2Health News:Over Six Million HIV Infected People In South Africa- Finds A Survey 3
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
(Date:10/30/2014)... -- , La fórmula de leche ... tolerancia a la proteína de leche de vaca  ... leche de la vaca (APLV) es la principal alergia alimentaria ... APLV se trataba eliminando las proteínas lácteas de ... posible adquirir tolerancia oral en un número significativo ...
(Date:10/30/2014)... Oct. 30, 2014  TWi Pharmaceuticals, Inc. today announced ... States Food and Drug Administration (FDA) on its Abbreviated ... 23 mg, the generic equivalent to Eisai Inc.,s Aricept® ... patients. TWi Pharmaceuticals is preparing to launch ... subsidiary, TWi Pharmaceuticals USA , at ...
Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... 28, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced plans ... ) on the clinical development of Nile,s proprietary natriuretic ... disease applications. "We are very pleased to ...
... Feb. 28, 2011 PAREXEL International Corporation (Nasdaq: ... presenting at the Raymond James Investors Conference in Orlando, FL. ... be making a presentation on PAREXEL at 2:50 p.m.  ET ... of this presentation will be available through the "Investors" ...
Cached Medicine Technology:Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 2Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 3PAREXEL International to Present at Raymond James Investors Conference 2
0.6mm Tip x10mm Shaft, Straight Shaft, 90 Degree Hook at Tip; overall length 120mm; in Titianium....
... SURPASS Perfusion Catheter is indicated ... stenotic portion of a coronary ... for the purpose of improving ... Catheters are also designed to ...
16mm from Mid-screw to Tips, blunt tips; overall length 110mm; Stainless Steel...
16mm from Mid-Screw to Blunt Tips, Gently Curved Blades; overall length 120mm; Stainless Steel...
Medicine Products: